JPM 2022: Amgen dials up biosimilar ambitions, with at least $4B in expected sales by 2030

JPM 2022: Amgen dials up biosimilar ambitions, with at least $4B in expected sales by 2030
fkansteiner
Tue, 01/11/2022 – 14:29